Publications by the researcher in collaboration with María Covadonga Martínez Díaz Caneja (20)

2024

  1. Accelerated Cortical Thinning in Schizophrenia Is Associated With Rare and Common Predisposing Variation to Schizophrenia and Neurodevelopmental Disorders

    Biological Psychiatry, Vol. 96, Núm. 5, pp. 376-389

  2. Cannabis use and cognitive biases in people with first-episode psychosis and their siblings

    Psychological Medicine

2023

  1. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  2. Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders

    Psychological Medicine, Vol. 53, Núm. 13, pp. 5986-5991

  3. Recent natural selection conferred protection against schizophrenia by non-antagonistic pleiotropy

    Scientific Reports, Vol. 13, Núm. 1

  4. Tobacco use in first-episode psychosis, a multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7265-7276

2022

  1. Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

    Schizophrenia, Vol. 8, Núm. 1

  2. Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

    Nature Communications, Vol. 13, Núm. 1

2021

  1. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

2020

  1. Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study

    Schizophrenia Research, Vol. 218, pp. 292-294

  2. Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial

    Schizophrenia Research, Vol. 223, pp. 271-278

  3. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

    Acta Psychiatrica Scandinavica, Vol. 141, Núm. 6, pp. 541-552

2018

  1. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

    The Lancet Psychiatry, Vol. 5, Núm. 10, pp. 797-807

  2. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis

    Schizophrenia Research, Vol. 193, pp. 188-196

  3. Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?

    Psychological Medicine, Vol. 48, Núm. 13, pp. 2247-2256

  4. Treated incidence of psychotic disorders in the multinational EU-GEI study

    JAMA Psychiatry, Vol. 75, Núm. 1, pp. 36-46

2016

  1. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project

    International Journal of Neuropsychopharmacology, Vol. 19, Núm. 4

  2. Cognitive reserve in bipolar disorder: Relation to cognition, psychosocial functioning and quality of life

    Acta Psychiatrica Scandinavica, Vol. 133, Núm. 5, pp. 386-398

2014

  1. Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra

    Revista de Psiquiatria y Salud Mental, Vol. 7, Núm. 4, pp. 166-178

  2. Identifying gene-environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations

    Schizophrenia Bulletin, Vol. 40, Núm. 4, pp. 729-736